Aquestive Therapeutics, Inc.
Warren, New Jersey, United States · Biopharma, Biotechnology, Healthcare
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Warren, New Jersey, United States
- Employees
- 150
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (AQST)
- Website
- aquestive.com
Recent activity at Aquestive Therapeutics, Inc.
- : SEC 8-K (7.01): Aquestive Therapeutics, Inc. is disclosing information related to an investor presentation scheduled for distribution at meetings with institutional investors and analysts. This event aims to provide insights into the Company’s strategic direction and project updates. The presentation is available online and may be updated through future filings. Notably, the presentation was dated November 2026, indicating its relevance to current discussions with potential investors. This proactive communication is intended to enhance investor relations and transparency.
- : SEC 8-K (7.01): This filing includes a Regulation FD Disclosure regarding an investor presentation to be conducted by Aquestive Therapeutics, Inc. on November 3, 2026. The presentation will be shared with institutional investors and analysts, providing insights into the company’s financial performance and recent developments. Accompanying this disclosure are the Q3 earnings supplemental materials and a press release detailing the financial results for the third quarter ended September 30, 2026. This information aims to maintain transparency and keep stakeholders informed about the company's strategic direction.
- : SEC 8-K (7.01): On October 15, 2026, Aquestive Therapeutics, Inc. announced the FDA's acknowledgment of its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, intended for treating Type I allergic reactions, including anaphylaxis. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, indicating the timeline for the agency's decision on the NDA. This disclosure is critical as it highlights significant progress in the drug approval process, which could impact the company's market position and future revenues.
Employee benefit plans
Aquestive Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
About Aquestive Therapeutics, Inc.: questions and answers
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company specializes in drug delivery technologies and is committed to improving patients' lives through its product pipeline. Their product candidate, Anaphylm™, aims to provide a new treatment option for severe allergic reactions. The company is headqua
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey, United States.
How many employees does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has about 150 employees.
What is the latest news on Aquestive Therapeutics, Inc.?
On Nov 05, 2026, SEC 8-K (7.01): Aquestive Therapeutics, Inc. is disclosing information related to an investor presentation scheduled for distribution at meetings with institutional investors and analysts. This event aims to provide insights into the Company’s strategic direction and project updates. The presentatio
Is Aquestive Therapeutics, Inc. a public company?
Yes. Aquestive Therapeutics, Inc. is publicly traded under the ticker AQST.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy